IMVACSNCT06860178
Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 13 words Show 7 more changesShow less
- Enrollment closed, study ongoing
- Final enrollment: 33542 participants (planned 40000)
- Primary completion date changed from estimate of May 2026 to Jul 30, 2026
- Study completion date: Dec 2027 to Dec 26, 2027
- Interventions: Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months (Other) to Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months (Other)
- Secondary endpoints: details revised at 5 of 10 entries
- Site details revised at 2 of 2 sites
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jun 2025 to Jun 10, 2025
- Site details revised at 2 of 2 sites
- Notable Start date: Apr 2025 to Jun 2025v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Malaria Incidence on 5-36 months at 12 months
Timeframe: from enrollment to 12 months
Secondary (10)
Malaria incidence among children aged 5-36 months over 24 and 36 months
Malaria incidence among children aged 3-59 months over 24 and 36 months
Malaria prevalence at peak transmission
Vaccine coverage
Occurrence of adverse events (AEs) and serious adverse events (SAEs) following R21/Matrix-M vaccination;
Show 5 moreShow less
Acceptability
Stakeholder perceptions of the feasibility on the vaccine delivery strategy in each group
Contextual and behavioural factors impeding or facilitating R21/Matrix-M vaccine uptake
Stakeholders and caregivers perceptions of the factors that enhance and/or constrain the succesful co,pletion of four doses of R21 and the key drivers of vaccination coverage
Incremental costs (per child vaccinated) and cost-effectiveness (per malaria case and separately, per DALY averted) of each vaccination strategy, calculated from a societal perspective
Arms and interventions
Control ArmNo intervention
Children aged 5-36 months will receive R21 via routine EPI vaccination (Year round in Burkina faso, or prior to the malaria season and SMC delivery in Mali)
Integrated SMC VaccinationOther
Children aged 3-59 months will receive 3-dose primary series aligned with SMC distribution in an annual campaign
Other: Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months
Sites
2 sites in 2 countries
Burkina Faso 1, Mali 1